Industry Insights

  1. February 2025 — CDMO Opportunities And Threats Report 3/7/2025

    Each month, Outsourced Pharma works in conjunction with PharmSource, part of GlobalData, to present its “Contract Manufacturing: Opportunities and Threats (CMOT) Report” to our readers. The report identifies CDMOs that might be impacted by key events affecting their clients, including company acquisitions, product acquisitions and licenses, product approvals, late clinical product terminations, and FDA rejections.

  2. Challenges In Manufacturing TIL For Clinical Trials 3/6/2025

    Tumor-infiltrating lymphocyte cell therapy shows promise for treating solid tumors, but its complex manufacturing profile brings a unique set of issues. Here are some things to watch out for.

  3. 4 Key Steps To Build Supply Chains For Later-Stage Clinical Trials In LMICs 3/6/2025

    Gates MRI's head of clinical supply discusses learnings and considerations that he keeps in mind for clinical trial supply chain/logistics.

  4. Understanding The New U.K. MHRA 'Draft Guideline On Individualised mRNA Cancer Immunotherapies' 3/5/2025

    The U.K.'s MHRA has released a new draft guideline outlining best practices for drug product design, CMC, and manufacturing of mRNA cancer immunotherapies using LNP delivery systems. The public comment period ends March 31.

  5. Distributed Cell Therapy Manufacturing Trade-Offs You Should Know About 3/5/2025

    For all its patient-centered benefits, producing personalized medicine at the point of care has pitfalls that are worth careful consideration.

  6. Addressing Challenges In Automated Visual Inspection Of Lyophilized Vials 3/4/2025

    Manual inspection is inefficient. Automated systems can struggle with the variability of lyo cake structures. Key technological advancements are coming to the forefront to address these issues.

  7. Why You Should Consider AI-Powered Digital Twins For Smart Manufacturing 3/3/2025

    Digital twins replicate a physical system using real-time data from IoT sensors, industrial control systems, MES, LIMS, etc. AI-driven digital twins add an extra advantage of predictive maintenance.

  8. Cell & Gene Therapies: Will 2025 Represent A Continuation Of FDA's 2024 Developments? 2/28/2025

    This article recaps the significant FDA regulatory considerations for cell and gene therapies in 2024. Will 2025 see a continuation of these efforts?

  9. Drug Design At The Speed Of Quantum 2/28/2025

    Using quantum computing to optimize drug design can identify the most effective molecular structures, and new therapeutic pathways could open the door to more personalized drugs.

  10. What FDA Draft Guidance Tells Us About In-Process Control Strategies 2/28/2025

    The draft aims to modernize the regulations in 21 CFR 211.110 catching up to progress in the field including advanced manufacturing and analytical technologies.